Medications for Atypical Hemolytic Uremic Syndrome

4 results

  • Bkemv (eculizumab-aeeb)

    (eculizumab-aeeb)
    Amgen Inc
    Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive. Not for Shiga toxin E. coli related HUS.

  • Epysqli (eculizumab-aagh)

    (Eculizumab-aagh)
    Samsung Bioepis Co., Ltd.
    Usage: EPYSQLI is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive. Limitations apply for STEC-HUS.

  • Soliris

    (ECULIZUMAB)
    Alexion Pharmaceuticals Inc.
    Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) in anti-AchR antibody positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 antibody positive adults. It is not for treatment of STEC-HUS.

  • Ultomiris

    (ravulizumab)
    Alexion Pharmaceuticals Inc.
    Usage: ULTOMIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) in patients aged one month and older, generalized myasthenia gravis (gMG) in AChR antibody-positive adults, and neuromyelitis optica spectrum disorder (NMOSD) in AQP4 antibody-positive adults.